US biopharmaceutical powerhouse Amgen is planning a $900m expansion of its Ohio manufacturing facility.
The biomedicine manufacturing facility was originally inaugurated in early 2024, and this expansion will bring the company's total investment into Ohio specifically to $1.4bn.
This news follows the impending threat of pharmaceutical import tariffs from the Trump Administration, which has prompted many big pharma players such as Johnson & Johnson, Roche, Novartis, Eli Lilly and Thermo Fisher Scientific to further invest into their US manufacturing capacity.
Through this facility expansion, the Kyprolis maker will significantly bolster its US biomanufacturing capabilities, while also creating more than 350 jobs for local professionals.
Since the Tax Cuts and Jobs Act was passed in 2017, Amgen has invested nearly $5bn in direct capital expenditures into the United States, resulting in a downstream output of around $12bn to the US economy.
"Amgen has been a US-based manufacturer of biologic medicines since 1988, and today's investment highlights our ongoing commitment to the expansion of US manufacturing," stated Chair and CEO of Amgen, Robert Bradway.
"Ohio offers a supportive business climate, a skilled workforce and a strategic location, making it a premier destination for growth."
The Ohio expansion follows Amgen's announcement detailing its $1bn investment into a second manufacturing plant in Holly Springs, North Carolina.